Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.68 |
| ▸ | TYK2 | P29597 | 2/20 | 0.68 |
| ▸ | JAK1 | P23458 | 1/20 | 0.68 |
| ▸ | GPR27 | Q9NS67 | 4/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | PYGL | P06737 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10427108 | 0.90 | JAK2 (0.77) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL29771435 | 0.90 | JAK2 (0.77) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL11575341 | 0.87 | ALDH1A1 (0.69) | JAK2TYK2JAK1MEN1KMT2A | |
| SCHEMBL15091807 | 0.86 | JAK2 (0.62) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL14228391 | 0.85 | JAK2 (0.69) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL17142908 | 0.84 | JAK2 (0.61) | JAK2TYK2JAK1AVPR2MEN1 | |
| SCHEMBL2681276 | 0.84 | RAB9A (0.69) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL2226570 | 0.84 | JAK2 (0.68) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL1753321 | 0.84 | JAK2 (0.68) | JAK2TYK2JAK1GPR27AVPR2 | |
| SCHEMBL2227567 | 0.83 | MEN1 (0.76) | JAK2TYK2JAK1GPR27AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005759-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY | 2013-01-03 | — | — | US | claimed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| WO-2011091209-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-07-28 | — | — | WO | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | claimed |
| US-20140213632-A1 | HCV Combination Therapy | STELLA APS (DK) | 2014-07-31 | — | — | US | disclosed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20140127159-A1 | HCV Combination Therapy | STELLA APS (DK) | 2014-05-08 | — | — | US | disclosed |
| US-20130005759-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY | 2013-01-03 | — | — | US | disclosed |
| US-20130005759-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY | 2013-01-03 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2011091209-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011091209-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-07-28 | — | — | WO | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | JAK2 679/4885TYK2 47/4885JAK1 297/4885 |
| US-20140127159-A1 | HCV Combination Therapy | HAVCR2, EIF2AK2, TIMP3 | JAK2 105/4885TYK2 3805/4885JAK1 502/4885 |
| US-20140213632-A1 | HCV Combination Therapy | HAVCR2, EIF2AK2, ZC3HAV1 | JAK2 93/4885TYK2 3108/4885JAK1 473/4885 |
| US-20130005759-A1 | SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 | HAVCR2, CCAR2, EIF2AK2 | JAK2 1847/4885TYK2 3743/4885JAK1 2719/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | JAK2 116/4885TYK2 381/4885JAK1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.